Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Multicenter, Open-label, Randomized Phase 3 Study of THIO Sequenced With Cemiplimab (LIBTAYO®) vs Investigator's Choice of Chemotherapy as Third-line Treatment in Advanced/Metastatic NSCLC

NCT06908304 is registered in ClinicalTrials.gov with Maia Biotechnology as lead sponsor.

NCT NCT06908304
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06908304 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Multicenter, Open-label, Randomized Phase 3 Study of THIO Sequenced With Cemiplimab (LIBTAYO®) vs Investigator's Choice of Chemotherapy as Third-line Treatment in Advanced/Metastatic NSCLC
Lead sponsor
Maia Biotechnology
Phase
Phase 3
Overall status
Recruiting
Start date
December 8, 2025
Completion date
December 31, 2027
Enrollment
300 (estimated)
Sites
15

Conditions

As the registry lists them; a condition with its own page is linked.

carcinoma, non-small -cell lung